Sclerosing encapsulating peritonitis as a rare cause of intestinal obstruction after the treatment of peritoneal mesothelioma: a case report and review of the literature

Zhizhan Ni¹#, Qing Chen²#, Chenshen Huang¹#, Song Wang¹, Qi Huang¹

¹Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, Shanghai, China; ²Department of General Surgery, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China

#These authors contributed equally to this work.

Correspondence to: Qi Huang. Department of General Surgery, Tongji Hospital, Tongji University School of Medicine, 389 Xincun Road, Shanghai 200065, China. Email: hqhq0078@163.com.

Abstract: Sclerosing encapsulating peritonitis (SEP) is a rare cause of intestinal obstruction that is characterized by a thick greyish-white fibrotic membrane encasing the small bowel. The clinical features are typically nonspecific, and they occasionally present with recurrent episodes of incomplete or complete intestinal obstruction. The etiology of SEP remains unclear, and the diagnosis is often delayed mainly due to the lack of specific symptoms. Here, we first report a patient who suffered from SEP after treatment for malignant mesothelioma (MM) with tumor resection supplemented with hyperthermic intraperitoneal chemotherapy (HIPEC) once and intraperitoneal chemotherapy (IPC) eight times. The patient was discharged ten days after surgery and was free of complications at the 4-month follow-up. In addition, we reviewed the published literature from PubMed, only 7 articles of 16 cases finally met the defined requirements. Nine cases of SEP after IPC and 7 cases of SEP after HIPEC were previously reported. We synthetically review the pathogenesis, treatments, and outcomes. In conclusion, SEP is a rare abdominal disease, which is difficult to diagnose preoperatively. CT scanning is the most helpful imaging method for the diagnosis of SEP. Surgery is the most effective method for diagnosis and treatment, if conservative treatment has no effect or abdominal symptoms are aggravated.

Keywords: Sclerosing encapsulating peritonitis (SEP); malignant mesothelioma (MM); intraperitoneal chemotherapy (IPC); case report

doi: 10.21037/tcr-20-3259
View this article at: http://dx.doi.org/10.21037/tcr-20-3259

Introduction

Sclerosing encapsulating peritonitis (SEP) is a rare clinical syndrome characterized by an inflammatory fibrocollagenous membrane, and segmental intestines are often encapsulated within (1). The clinical features are typically nonspecific, and they occasionally present with recurrent episodes of incomplete or complete intestinal obstruction (2). Early-stage symptoms of the disease include fever, weight loss, constipation, abdominal distention, and nausea. However, as the disease progresses, thickened membranes can encapsulate the intestines, and the signs of intestinal obstruction become more obvious (2,3). Although the factors that lead to SEP remain to be fully elucidated, intraperitoneal chemotherapy (IPC) is widely reported to be a promoter of disease progression (4,5). Here, we first report a patient who suffered from SEP after treatment of malignant mesothelioma (MM) with tumour resection supplemented with hyperthermic intraperitoneal chemotherapy (HIPEC) once and IPC eight times. We present the following article in accordance with the CARE reporting checklist (available at http://dx.doi.org/10.21037/tcr-20-3259).
Case presentation

A 32-year-old woman presented in January 2019 with acute crampy abdominal pain and other signs of acute small bowel obstruction, including distention, vomiting and constipation. No fever or other symptoms were present. Medical history indicated MM resection at 28 and postoperative HIPEC with cisplatin at a dose of 600 mg once supplemented by IPC with cisplatin at a dose of 50 mg and intravenous chemotherapy with pemetrexed at a dose of 800 mg eight times. She experienced several episodes of incomplete bowel obstruction since MM resection and was relieved through conservative treatment.

On examination, marked abdominal distension and a mass in the central abdomen were found. Laboratory blood tests showed leucocytosis and elevated C-reactive protein (CRP) levels. X-ray tests showed dilation of small intestine loops, intestinal fluid retention and multiple air-fluid levels (data not shown). Abdominal computed tomography (CT) scanning revealed that clumped small intestine loops were surrounded and confined within a membranous cavity (Figure 1A). Transverse CT scanning sections showed dilated small intestines with multiple air-fluid levels that were enwrapped and isolated by irregularly shaped membranous tissues (Figure 1B).

The decision was made to perform an exploratory laparotomy due to obstinate small bowel obstruction. During the surgery, we found complete encapsulation of the proximal jejunum to the distal ileum by prominently thickened fibrous membranes (Figure 2A, B). SEP was confirmed intraoperatively, and meticulous adhesiolysis was performed. All the adhesions and cocoon membranes were released by blunt or sharp separation. The entire intestines were completely released without causing any secondary damage, and encapsulating peritonea were partially resected and sent for histological examination (Figure 2C). Symptoms of small bowel obstruction were relieved, and bowel movements were recovered at day 9 postoperationally. The patient was free of complications with normal bowel function at the 4-month follow-up.

The resected abdominal cocoon (AC) was histologically processed by hematoxylin and eosin staining (5 minutes each in room temperature). Histological examination of the resected membrane showed high proliferation of fibroconnective tissue associated with peritoneal mesothelioma (Figure 3A, B).

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.

Methods

The literature search was conducted using the PubMed
Figure 2 Intraoperative photographs of encapsulated small intestine. (A,B) Complete encapsulation of the upper jejunum and the ileocecal small intestine by prominently thickened fibrous membranes was detected. (C) The encapsulated intestinal loops were completely released in surgery.

Figure 3 The paraffin-embedded tissue sections were used for examination of hematoxylin and eosin (HE) staining. Pathological examination of resected membranous tissue revealed high proliferation of fibroconnective tissue along with peritoneal mesothelioma tissue.

database up to December 2019 with the following index words: “abdominal cooon”[Title] OR “sclerosing encapsulating peritonitis”[Title] OR “encapsulating peritoneal sclerosis”[Title] OR “peritoneal fibrosis”[Title] OR “intraperitoneal chemotherapy”[Title]. The search only included case reports, and the search was limited to papers in the English language.

Results

Of the 2,790 papers found, only 465 papers were included as case reports. Seven articles of 16 cases finally met the defined requirements of SEP after IPC or HIPEC treated by the surgical approach. Nine cases of SEP after IPC and 7 cases of SEP after HIPEC were previously reported and are summarized in Table 1 (4,6-11).
Table 1 Reported cases of sclerosing encapsulating peritonitis after intraperitoneal chemotherapy treated by the surgical approach

<table>
<thead>
<tr>
<th>No</th>
<th>Author</th>
<th>Years</th>
<th>Primary Disease</th>
<th>Chemotherapy</th>
<th>Sex</th>
<th>IP/HIPEC</th>
<th>Treatment</th>
<th>SEP after initial surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Braly</td>
<td>1986</td>
<td>Ovarian cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Female</td>
<td>IP</td>
<td>Laparotomy</td>
<td>Unknown</td>
</tr>
<tr>
<td>2</td>
<td>Braly</td>
<td>1986</td>
<td>Ovarian cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Female</td>
<td>IP</td>
<td>Laparotomy</td>
<td>Unknown</td>
</tr>
<tr>
<td>3</td>
<td>Braly</td>
<td>1986</td>
<td>Ovarian cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Female</td>
<td>IP</td>
<td>Laparotomy</td>
<td>Unknown</td>
</tr>
<tr>
<td>4</td>
<td>Vlasveld</td>
<td>1992</td>
<td>Mesothelioma</td>
<td>Metoxantrone</td>
<td>Male</td>
<td>IP</td>
<td>Surgery</td>
<td>Alive, 48 months</td>
</tr>
<tr>
<td>5</td>
<td>Atiq</td>
<td>1993</td>
<td>Gastric cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Unknown</td>
<td>IP</td>
<td>Surgery</td>
<td>Unknown</td>
</tr>
<tr>
<td>6</td>
<td>Atiq</td>
<td>1993</td>
<td>Gastric cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Unknown</td>
<td>IP</td>
<td>Surgery</td>
<td>Unknown</td>
</tr>
<tr>
<td>7</td>
<td>Atiq</td>
<td>1993</td>
<td>Gastric cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Unknown</td>
<td>IP</td>
<td>Surgery</td>
<td>Unknown</td>
</tr>
<tr>
<td>8</td>
<td>Atiq</td>
<td>1993</td>
<td>Gastric cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Unknown</td>
<td>IP</td>
<td>Surgery</td>
<td>Unknown</td>
</tr>
<tr>
<td>9</td>
<td>Atiq</td>
<td>1993</td>
<td>Gastric cancer</td>
<td>Cisplatin, 5-FU</td>
<td>Unknown</td>
<td>IP</td>
<td>Laparotomy</td>
<td>Unknown</td>
</tr>
<tr>
<td>10</td>
<td>Aihara</td>
<td>2003</td>
<td>Gastric cancer</td>
<td>Cisplatin, mitomycin c</td>
<td>Female</td>
<td>HIPEC</td>
<td>Surgery</td>
<td>Alive, 21 months</td>
</tr>
<tr>
<td>11</td>
<td>Katsushi</td>
<td>2014</td>
<td>Colon cancer</td>
<td>Oxaliplatin, 5-FU, Mitomycin C</td>
<td>Male</td>
<td>HIPEC</td>
<td>Surgery oral steroid therapy</td>
<td>Alive, 24 months</td>
</tr>
<tr>
<td>12</td>
<td>Gabriel</td>
<td>2018</td>
<td>Appendiceal DPAM</td>
<td>Oxaliplatin</td>
<td>Female</td>
<td>HIPEC</td>
<td>Laparotomy</td>
<td>Alive, 27 months</td>
</tr>
<tr>
<td>13</td>
<td>Gabriel</td>
<td>2018</td>
<td>Colon Adenocarcinoma</td>
<td>Oxaliplatin</td>
<td>Male</td>
<td>HIPEC</td>
<td>Laparotomy</td>
<td>Alive, 4 months</td>
</tr>
<tr>
<td>14</td>
<td>Gabriel</td>
<td>2018</td>
<td>Cystic mesothelioma</td>
<td>Cisplatin, Doxorubicin, Ifosfamide, MESNA</td>
<td>Male</td>
<td>HIPEC</td>
<td>Surgery</td>
<td>Alive, 6 years</td>
</tr>
<tr>
<td>15</td>
<td>Gabriel</td>
<td>2018</td>
<td>Appendiceal DPAM</td>
<td>Mitomycin C, Doxorubicin, 5-FU, Leucovorin</td>
<td>Female</td>
<td>HIPEC</td>
<td>Surgery</td>
<td>Alive, 6 years</td>
</tr>
<tr>
<td>16</td>
<td>Clodagh</td>
<td>2018</td>
<td>Colon cancer</td>
<td>Oxaliplatin, 5-FU, Mitomycin C</td>
<td>Male</td>
<td>HIPEC</td>
<td>Laparotomy</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

IP, intraperitoneal perfusion chemotherapy; HIPEC, hyperthermic intraperitoneal chemotherapy; 5-FU, 5-fluorouracil; DPAM, disseminated peritoneal adenomucinosis; MESNA, 2-mercaptoethanesulfonate sodium.

Discussion

SEP is a rare clinical syndrome characterized by an inflammatory fibro-collagenous membrane, and segmental intestines are often encapsulated within, leading to recurrent small bowel obstruction (1). Although the aetiology still requires further investigation, SEP is commonly classified as primary (idiopathic) and secondary (12). Primary SEP, which is also known as abdominal cocoon (AC), was previously reported in adolescent females with fallopian tube inflammation or irregular menstruation presumably due to chemical peritonitis induced by retrograde infection (13). Other causative diseases of primary SEP, such as hereditary omentum heteroplasia (14) and peritoneal bacterial infection (15), have also been reported. Secondary SEP, which is presented more commonly in previous reports, develops when a local or systemic factor triggers inflammatory cascades in the peritoneum (12). SEP is most commonly triggered by long-term peritoneal dialysis (PD) (16,17) but is also reported to be associated with other factors, including medications (18,19), infections (20,21), abdominal tumour surgeries and postoperative chemotherapy (4,5,9), peritoneal shunts (22), recurrent episodes of peritonitis (23) and autoimmune disorders (24,25). However, the pathophysiology of these various factors triggering SEP is not well studied with the exception of PD, which is referred to as the “two-hit” hypothesis (26,27). Non-inflammatory peritoneal sclerosis accumulates in repeated PD (“first hit”) followed by precipitation of a pro-inflammatory cascade (transforming growth factor β1, interleukin-6, etc.) and pro-angiogenic (vascular endothelial growth factor) cytokines (“second-hit”), leading to transdifferentiation of peritoneal mesothelial cells and formation of inflammatory fibro-collagenous membranes.

To our knowledge, IPC and HIPEC could also cause peritoneal fibrosis and repeated intestinal obstruction due to dense adhesions (4,5,9). Markman et al. first suggested...
that the use of IPC would cause extensive adhesion formation in 1986 (28). In his study, 1,103 patients were treated with IPC. Two cases reported extensive sclerosis related to cisplatin. Jacquet et al. reported a retrospective study including 196 patients treated with at least 1 cycle of early postoperative IPC with 5-fluorouracil (5-FU) and mitomycin C (29). Among those patients, 4 developed peritoneal fibrosis due to dense adhesions. According to the "two-hit" theory in PD patients, peritoneal sclerosis and fibrosis formation resulting from IPC can be considered the "first hit". Additional pro-inflammatory inducing incidents would be required as a "second hit" for SEP development. There are limited clinical data and reports on SEP caused by HIPEC and IPC (Table 1). The generation of SEP mostly resulted from tumours of the gynaecology and digestive system. In 9 cases of SEP after IPC, at least 1 cycle of postoperative cisplatin and 5-FU was performed. Among the 7 cases of HIPEC, 2 cases accepted oxaliplatin, and 2 cases accepted mitomycin C and 5-FU. To some extent, the repeated treatment of IPC is similar to that of PD for renal failure. According to the "two-hit" hypothesis, this could be a trigger for SEP.

In our case, the primary disease of SEP was MM, which is a rare disease that develops from mesothelial cells covering the surface of serous membranes (30). MM accounts for approximately 10–20% of all mesotheliomas and has an estimated incidence of 40–60 in 1,000,000 per year (31). CRS and HIPEC are the traditional treatments for MM. In previous studies, only Vlasveld reported a case of SEP caused by MM after intravenous chemotherapy with metoxantrone (11). The patient in our study received 6 cycles of intravenous chemotherapy with cisplatin and 1 additional cycle of HIPEC cisplatin. This is the first reported patient treated with both IPC and HIPEC reported to be diagnosed with SEP.

Laparotomy is always the gold-standard diagnostic approach for SEP (2,32,33) and is often performed in patients who fail conservative therapy. Surgical exploration confirms the diagnosis, determines the range and severity of bowel obstruction and determines whether a segmental necrotic bowel needs to be removed (12). To reduce the possibility of intestinal injury during the perioperative period that could cause complications, such as postoperative intestinal leakage and short-intestine syndrome, adhesiolysis is often sufficient to relieve intestinal obstruction (34). In this patient, we performed meticulous adhesiolysis without membrane excision. The patient was free of uncomfortable complaints at the 4-month follow-up.

Conclusions

In conclusion, SEP is a rare abdominal disease and is difficult to diagnose preoperatively. When a patient shows the main clinical features of intestinal obstruction after HIPEC or IP similar to this patient, SEP should be considered. CT scanning is the most helpful imaging method for the diagnosis of SEP. If conservative treatment has no effect or abdominal symptoms are aggravated, surgery is the last option. Laparotomy plays an important role in its diagnosis and treatment. The aim of the operation is to release bowel encapsulation and preserve the function of the small intestines as much as possible.

Acknowledgments

We appreciate the patient’s approval to present this case, and we also acknowledge the support from the Department of General Surgery, Department of Pathology, and Department of Radiology in patient diagnosis and treatment.

Funding: This study was funded by the Shanghai Science and Technology Innovation Action Plan (Grant No. 19441905700) and the Clinical Research and Cultivation Project of Shanghai Tongji Hospital [Grant No. ITJ (ZD) 1802, ITJ (ZD) 1804].

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at http://dx.doi.org/10.21037/tcr-20-3259

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tcr-20-3259). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient.

Open Access Statement: This is an Open Access article
distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References
